Gain Therapeutics Inc.

1.79
-0.10 (-5.29%)
At close: Apr 03, 2025, 3:59 PM
1.75
-2.18%
After-hours: Apr 03, 2025, 06:24 PM EDT
-5.29%
Bid 1.68
Market Cap 49.74M
Revenue (ttm) n/a
Net Income (ttm) n/a
EPS (ttm) -0.89
PE Ratio (ttm) -2.01
Forward PE -2.65
Analyst Buy
Ask 1.97
Volume 201,164
Avg. Volume (20D) 231,876
Open 1.83
Previous Close 1.89
Day's Range 1.74 - 1.82
52-Week Range 0.89 - 4.04
Beta 0.14

About GANX

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing s...

Industry Biotechnology
Sector Healthcare
IPO Date Mar 19, 2021
Employees 29
Stock Exchange NASDAQ
Ticker Symbol GANX
Full Company Profile

Analyst Forecast

According to 5 analyst ratings, the average rating for GANX stock is "Buy." The 12-month stock price forecast is $7.5, which is an increase of 318.99% from the latest price.

Stock Forecasts

Earnings Surprise

Gain Therapeutics has released their quartely earnings on Mar 27, 2025:
  • Revenue of $0 misses estimates by $30K, with NaN% YoY growth.
  • EPS of -0.11 exceeds estimates by 0.06, with 62.07% YoY growth.
  • Next Earnings Release

    Gain Therapeutics Inc. is scheduled to release its earnings on May 13, 2025, before market opens.
    Analysts project revenue of ... Unlock content with Pro Subscription
    5 months ago
    +14.68%
    Gain Therapeutics shares are trading higher after ... Unlock content with Pro Subscription
    5 months ago
    +17.03%
    Gain Therapeutics shares are trading higher after the company announced the presentation of new evidence supporting the disease-modifying activity of Gt-02287 in preclinical animal models of both GBA-1 and idiopathic Parkinson's disease.